Navigation Links
Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
Date:5/5/2009

ROCKVILLE, Md., May 5 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company focused on diseases of epidemic potential, announced today the start of its Phase 1B trial for SQ109 with the dosing of the first cohort of volunteers. SQ109, a new diamine antibiotic intended to replace one or more of the current first-line antitubercular drugs and simplify patient therapy, was granted U.S. FDA Fast Track designation and FDA/EMEA Orphan Drug Designation in 2007. SQ109 shows superior antibacterial activity against drug sensitive and both multi-drug resistant and extensively-drug resistant (MDR and XDR) Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). The Phase 1B study will assess safety, pharmacokinetics and tolerability of multiple ascending doses of SQ109 in three cohorts of healthy volunteers.

"We are pleased to begin this Phase 1B safety trial and to continue the clinical development of SQ109, a potentially valuable new drug candidate for the treatment of both uncomplicated and drug resistant TB," said Dr. Carol Nacy, Sequella CEO. "With the growing number of new TB cases within HIV-infected populations, there is no time to waste. Clinicians and patients alike are desperate for new drugs to shorten treatment times and improve patient outcomes. In a global world, the safety assessment of a new drug candidate with the antitubercular properties of SQ109 is an important milestone for patients on every continent, including North America."

The SQ109 Phase 1B trial is being conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), through a contract awarded to Dynport Corporation. The investigative site is the Quintiles Phase 1 facility in Overland Park, Kansas.

About Sequella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for diseases of epidemic potential. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

About the NIH and NIAID

The NIH -- The Nation's Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov. NIAID conducts and supports research -- at NIH, throughout the United States, and worldwide -- to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.


'/>"/>
SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
2. Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
3. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
4. Psylin Neurosciences Commences Development of Compound for Depression
5. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
6. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
7. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
8. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
9. SenesTech, Inc. Commences Product Registration Process With Australian Government
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... Pleasant Prairie, WI (PRWEB) , ... June 23, ... ... sciences consultancy focused on quality, regulatory and technical consulting, provides a free ... webinar is presented on July 13, 2016 at 12pm CT at no charge. ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):